Restoracs

Roughly two years after Stablix embarked on a mission to stabilize certain proteins whose insufficiency leads to disease, Vertex Pharmaceuticals announced it’s coming along for the ride. Stablix and Vertex unveiled a collaboration on Tuesday that gives Vertex an exclusive license to certain molecules discovered under the pact. Stablix has billed its platform as a “first-in-category” approach that’s essentially the inverse of PROTACs. The idea is to recruit enzymes called deubiquitinases, or DUBs, to restore useful proteins for potential use in rare diseases, oncology and immunology. Stablix is calling their drugs RESTORACs. Unlock this story instantly and join 166,100+ biopharma pros reading Endpoints daily — and it's free.